Omega-3 & Lipid Membrane Health

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Omega-3 & Lipid Membrane Health - References

---

1. Pharmacodynamics & Mechanism of Action

Long-chain polyunsaturated fatty acids—Eicosapentaenoic Acid (EPA, 20:5n-3) and Docosahexaenoic Acid (DHA, 22:6n-3)—govern biophysical membrane fluidity, lipid raft organization, and inflammatory resolution.

• Membrane Biophysics & Synaptic Signaling: DHA constitutes $30\text{–}40\%$ of total fatty acids in neuronal and retinal phosphatidylserine/phosphatidylethanolamine bilayers, lowering membrane phase transition temperature and facilitating GPCR conformation, ion channel kinetics, and vesicular exocytosis (synergistic with Cholinergics (Alpha-GPC, Citicoline) via the Kennedy pathway).
• Competitive Eicosanoid Modulation: Displaces pro-inflammatory Arachidonic Acid (AA, 20:4n-6) from membrane sn-2 phospholipids, shifting cyclooxygenase (COX) and lipoxygenase (LOX) output from 2-series prostaglandins (${\text{PGE}}_2$, ${\text{TXA}}_2$) and 4-series leukotrienes (${\text{LTB}}_4$) toward less inflammatory 3-series prostanoids and 5-series leukotrienes.
• Active Resolution of Inflammation (SPMs): Serves as the obligate substrate for Specialized Pro-resolving Mediators—including E-series Resolvins (RvE1–RvE3 from EPA) and D-series Resolvins, Protectins (Neuroprotectin D1), and Maresins (from DHA)—which actively terminate neutrophil infiltration and stimulate macrophage efferocytosis via GPR32 and ChemR23 receptors.
• Transcriptional Lipid Control: Activates $\text{PPAR}-\alpha /\gamma$ and suppresses SREBP-1c, reducing hepatic VLDL-triglyceride synthesis by $20\text{–}45\%$ at pharmacological doses.

---

2. Pharmacokinetics & Molecular Carriers

Molecular Form	Bioavailability Index (vs. rTG)	Pancreatic Lipase Dependency	Key Structural & Clinical Attributes
Re-esterified Triglyceride (rTG)	$100\text{–}124\%$	Moderate	Highest systemic $\text{AUC}$ and rapid RBC Omega-3 Index incorporation; low TOTOX when stabilized
Phospholipid (PL / Krill / Roe)	$110\text{–}130\%$ (per mg)	Low	Amphiphilic; generates Lysophosphatidylcholine-DHA (LPC-DHA) which crosses the BBB via Mfsd2a transporter
Free Fatty Acid (FFA)	~100%	Minimal	High absorption independent of dietary fat, but prone to GI irritation and lipid peroxidation
Ethyl Ester (EE)	$60\text{–}73\%$ (fasted: $<25\%$)	Very High (requires carboxylesterase)	Requires high-fat meal co-ingestion; used in prescription icosapent ethyl (Vascepa)

---

3. Dosing, Cycling & Synergies

• Standard Protocol: $2,000\text{–}4,000\text{ mg/day}$ combined EPA + DHA in rTG or phospholipid form (verify certificate of analysis: Peroxide Value $<5\text{ mEq/kg}$, Anisidine Value $<20$, TOTOX $<15$).
  • Cardiovascular / Mood Emphasis: Higher EPA ratio ($2:1$ or $3:1$ EPA:DHA, $2\text{–}4\text{ g/day}$ EPA).
  • Neuroprotection / Retinal Emphasis: $1,000\text{–}1,500\text{ mg/day}$ DHA + phospholipid LPC-DHA carrier.
• Synergies: Low-dose aspirin ($81\text{ mg}$ acetylates COX-2 to generate aspirin-triggered 18R-resolvins), astaxanthin/tocopherols (prevents in vivo lipid peroxidation), and Cholinergics (Alpha-GPC, Citicoline) + uridine (Kennedy pathway synaptogenesis).
• Contraindications & Biomarkers to Monitor:
  • Contraindications/Precautions: High doses ($4\text{ g/day}$, particularly ethyl esters) show a slight dose-dependent increase in atrial fibrillation risk in predisposed cardiovascular cohorts; monitor bleeding time if combined with dual antiplatelet or anticoagulant therapy.
  • Biomarkers: RBC Omega-3 Index (target: $8.0\text{–}12.0\%$ of total erythrocyte fatty acids), AA:EPA Ratio (target: $1.5:1\text{ to }3:1$), fasting triglycerides, hs-CRP, and ApoB (DHA can modestly increase LDL particle size and LDL-C in hyper-responders).

---

4. Key Scientific Evidence Summary

• Omega-3 Index & Coronary Mortality: Harris & Von Schacky (2004) established that an erythrocyte Omega-3 Index $\ge 8\%$ is associated with an $\sim 70\text{–}90\%$ reduction in sudden cardiac death risk compared to an index $<4\%$.
• REDUCE-IT Cardiovascular Trial: Bhatt et al. (2019) demonstrated in NEJM ($N=8,179$) that $4\text{ g/day}$ icosapent ethyl reduced major adverse cardiovascular events (MACE) by $-25\%$ ($\text{HR }0.75,p<0.001$) and cardiovascular death by $-20\%$.
• Bioavailability of rTG vs. EE: Dyerberg et al. (2010) and Neubronner et al. (2011) proved that re-esterified triglycerides achieve a $+50\text{–}70\%$ higher relative bioavailability and faster Omega-3 Index elevation than ethyl esters.

See full study breakdowns in Omega-3 & Lipid Membrane Health - References.